Leonard Appleman
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Leonard Appleman sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Leonard Appleman: 4 sponsored US clinical trials, none currently recruiting.
Leonard Appleman sponsors 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 4 completed. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Metastatic Transitional Cell Cancer of the Urothelial Tract, with 1 trials.
Upper-quartile sponsor footprint
Leonard Appleman sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
4 total, page 1 of 1
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
NCT01550367
Study of GemOx and Vandetanib in Advanced Solid Malignancy
NCT00660725
A Study of Imatinib and Docetaxel in Prostate Cancer
NCT00251225
Study of Docetaxel and Oxaliplatin in Metastatic Transitional Cell Cancer (TCC) of the Urothelial Tract
NCT03159143
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
How the Leonard Appleman early-phase archive is shaped
4 indexed studies, none listed as recruiting (0% open); 4 completed (100%).
Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Metastatic Transitional Cell Cancer of the Urothelial Tract (1 trial), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Leonard Appleman: archived-pipeline peers nationwide
Peers matched on 4 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Leonard Appleman sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 archived trials
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Leonard Appleman page
4 registered trials is a research-attention snapshot, not an endorsement of Leonard Appleman or any single study.
- None of Leonard Appleman's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Metastatic Transitional Cell Cancer of the Urothelial Tract is the condition Leonard Appleman studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Metastatic Transitional Cell Cancer of the Urothelial Tract trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Leonard Appleman pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.